It is important now more than ever to keep yourself compliant and consistent with your home exercise program. At minimum, you should be performing 2-3 stretches of your leg muscles regardless of any ambulatory issues.For patients who usually go outdoors and cannot due to the weather, extra standing and walking exercises are recommended, IF standing and walking exercises have been prescribed.

Congratulations to Dr. Saud A. Sadiq who has been recognized in Castle Connolly's "America's Top Doctors" 14th ed. and "Top Doctors: New York Metro Area" 18th ed.

Due to the impending storm and weather conditions, the IMSMP will be closed on Tuesday, January 27th. For any emergencies, a neurologist will be available by calling (212) 265-8070.

1/16/15 - iConquerMS™ is a project associated with the Accelerated Cure Project. iConquerMS™ allows patients to independently enter their health data into a secure online database, where it will be analyzed in conjunction with that of thousands of others living with MS. In their words:

by Dr. James W. Stark

1/8/15 - The December 29th online issue of the journal, JAMA Neurology, published results on the safety and efficacy of a stem cell project currently funded by the National Institute of Health (NIH). This is valuable research in the field of Multiple Sclerosis, but is NOT the same as the phase I REPARATIVE stem cell trial currently underway at the IMSMP.

12/8/14 - 'Tis the season for snow and less sunshine. Supplementing with vitamin D during these cold months becomes even more important. For the appropriate dose, check with your neurologist or IMSMP patients can schedule a consult with Dr. Bates, our naturopathic doctor.

by Dr. James W. Stark

11/25/14 - Plegridy was recently approved by the FDA for the treatment of relapsing forms of MS and is now available for use. Plegridy is another interferon, specifically pegylated interferon B-1a. It is similar to other interferons currently available but is administered every two weeks by a subcutaneous injection. Side effects were similar to other interferons, however, because it is administered every two weeks, side effects were seen less frequently than...

11/17/14 - The FDA has approved Lemtrada (Alemtuzumab) for the treatment of RRMS. Lemtrada has been available to treat MS in Europe and Canada and has also been used in the United States to treat leukemia. Lemtrada will likely be reserved for patients with very aggressive forms of relapsing MS, as there are a number of safety considerations with this medication.


Subscribe to IMSMP Update